Drug Trial Demand Rebounds: Medpace Bookings Hit Record High as Cancellations Decline

Whether the drug development environment is improving can be assessed not only from pharmaceutical companies’ trial results, but also through the clinical research organizations that conduct those trials. Medpace recorded record net new bookings in the second quarter of 2026, while a factor that had previously weighed on performance—clients canceling or scaling back programs—also eased significantly, making the near-term outlook more stable than before.

Medpace is a global contract research organization (CRO) that primarily provides clinical development services to small and midsize biotech and pharmaceutical companies, covering trial design, execution, and data management. Such clients typically lack the in-house clinical teams of large pharmaceutical companies and are more vulnerable to the fundraising environment, making changes in Medpace’s bookings one indicator of activity among early-stage and midsize drug developers.

CEO August Trundle said on the earnings call that second-quarter cancellations remained under control, helping net new bookings reach a record high; management also noted that cancellation volume had declined significantly. Oncology was an important source of strong bookings during the quarter, indicating that cancer drug development remains a key pillar of demand for outsourced clinical trials.

Another positive signal came from the front end of the business. Management said the number of client requests for services increased from both the previous quarter and the same period last year, and that the operating environment remained constructive after entering July. This does not mean that every inquiry will turn into a formal trial, but the expansion in proposal activity at least indicates that more developers are reassessing or advancing clinical programs.

As of this update, Medpace expects approximately $1.96 billion of backlog to convert into revenue over the next 12 months. The substantial backlog increases visibility into near-term revenue and supports the market’s view that recent performance is improving. However, the actual pace of conversion will still depend on patient recruitment, trial progress, protocol adjustments, and clients’ funding conditions.

Accordingly, these results are better interpreted as a near-term improvement in the clinical outsourcing market, rather than evidence that the entire biotech financing cycle has fully reversed. Medpace’s client base is concentrated among companies with more limited resources, and a single research and development failure, fundraising delay, or strategic change could once again lead to trial delays and order cancellations. The key questions ahead are whether the increase in requests can continue to translate into formal contracts, and whether the record bookings can be converted into revenue as expected.